Genomic Valley Biotech has informed about the disclosures of reasons for encumbrance by promoter of listed companies under Regulation 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October 06, 2019 for Yogesh Agrawal.
The above information is a part of company’s filings submitted to BSE.